What the FDA labels say about taking them together
Hydroxychloroquine and remdesivir
Remdesivir's FDA label of July 29, 2026 names hydroxychloroquine in its drug interactions section; the hydroxychloroquine labels PlainMeds reads (2) do not name remdesivir. The remdesivir label: “… culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended.”
Check it at the source: the hydroxychloroquine FDA label on DailyMed (effective October 8, 2024, ANI Pharmaceuticals, Inc.); the remdesivir FDA label on DailyMed (effective July 29, 2026, Gilead Sciences, Inc.).
What does the hydroxychloroquine label say about remdesivir?
Hydroxychloroquine's label (effective October 8, 2024) and its 1 other brand-application label do not name remdesivir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SOVUNA), ANI Pharmaceuticals, Inc., effective October 8, 2024 (SPL set dd441154-b196-4d4c-bc56-2e37f345ef8d), via openFDA; the full label on DailyMed
What does the remdesivir label say about hydroxychloroquine?
Remdesivir label, drug interactionsDRUG INTERACTIONS 7.1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended [see Warnings and Precautions (5.3) and Microbiology (12.4) ].
Remdesivir label, warnings and precautionsDiscontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation. ( 5.2 ) Risk of reduced antiviral activity when coadministered with chloroquine phosphate or hydroxychloroquine sulfate:
Source: FDA drug label (Veklury), Gilead Sciences, Inc., effective July 29, 2026 (SPL set c0978fa8-53ff-4ca2-82a7-567fd3e958ca), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Hydroxychloroquine | Remdesivir | |
|---|---|---|
| Labeled for | Rheumatoid arthritis | COVID-19 |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.149 per tablet 200 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once